Amy Qin

996 total citations · 2 hit papers
12 papers, 720 citations indexed

About

Amy Qin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Amy Qin has authored 12 papers receiving a total of 720 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 2 papers in Molecular Biology. Recurrent topics in Amy Qin's work include HER2/EGFR in Cancer Research (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Vascular Tumors and Angiosarcomas (3 papers). Amy Qin is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Vascular Tumors and Angiosarcomas (3 papers). Amy Qin collaborates with scholars based in United States, United Kingdom and Italy. Amy Qin's co-authors include Robert Ilaria, Jan Cosaert, Ashwin Shahir, Damien M. Cronier, Mark Agulnik, Ilaria Conti, Michael B. Livingston, Bartosz Chmielowski, Matthew M. Cooney and Anthony Elias and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Amy Qin

11 papers receiving 709 citations

Hit Papers

Olaratumab and doxorubicin versus doxorubicin alone for t... 2016 2026 2019 2022 2016 2023 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
    2016 436 citations William D. Tap, Robin L. Jones et al. The Lancet profile →
  2. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study
    2023 124 citations Eric Van Cutsem, Maria Di Bartolomeo et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amy Qin United States 8 487 472 130 99 95 12 720
Ashwin Shahir United States 11 476 1.0× 400 0.8× 172 1.3× 101 1.0× 65 0.7× 26 677
Douglas Adkins United States 8 389 0.8× 360 0.8× 120 0.9× 79 0.8× 74 0.8× 19 659
Hanna Koseła-Paterczyk Poland 15 431 0.9× 418 0.9× 133 1.0× 76 0.8× 217 2.3× 75 780
Nadia Hindi Spain 16 667 1.4× 445 0.9× 162 1.2× 126 1.3× 106 1.1× 81 889
Yvonne Schrage Netherlands 15 577 1.2× 240 0.5× 104 0.8× 51 0.5× 126 1.3× 52 820
Guowen Wang China 18 554 1.1× 475 1.0× 102 0.8× 80 0.8× 183 1.9× 29 873
Veridiana Pires de Camargo Brazil 9 641 1.3× 539 1.1× 207 1.6× 167 1.7× 68 0.7× 26 878
Kelly Scheu United States 5 359 0.7× 389 0.8× 80 0.6× 91 0.9× 154 1.6× 10 723
Thibaud Valentin France 12 324 0.7× 202 0.4× 83 0.6× 107 1.1× 72 0.8× 38 505
Zsuzsa Pápai Hungary 9 750 1.5× 566 1.2× 235 1.8× 180 1.8× 170 1.8× 10 908

Countries citing papers authored by Amy Qin

Since Specialization
Citations

This map shows the geographic impact of Amy Qin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Qin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Qin more than expected).

Fields of papers citing papers by Amy Qin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Qin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Qin. The network helps show where Amy Qin may publish in the future.

Co-authorship network of co-authors of Amy Qin

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Qin. A scholar is included among the top collaborators of Amy Qin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Qin. Amy Qin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Verhoeven, Rob H.A., et al.. (2025). Trastuzumab Deruxtecan Versus Ramucirumab-Paclitaxel as Second-Line Therapy for Patients With HER2-Positive Gastric or GEJ Adenocarcinoma. Journal of the National Comprehensive Cancer Network. 23(10).
2.
Cutsem, Eric Van, Maria Di Bartolomeo, Elizabeth Smyth, et al.. (2023). Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. The Lancet Oncology. 24(7). 744–756. 124 indexed citations breakdown →
3.
Powell, Charles A., Shanu Modi, Hiroji Iwata, et al.. (2021). Abstract CT167: Pooled analysis of drug-related interstitial lung disease (ILD) in 8 single-arm trastuzumab deruxtecan (T-DXd) studies. Cancer Research. 81(13_Supplement). CT167–CT167. 11 indexed citations
4.
Fuchs, Charles S., Javad Shahidi, Lijoy K. Mathew, Amy Qin, & Eric Van Cutsem. (2020). A phase II trial of [fam-] trastuzumab deruxtecan (T-DXd, DS-8201a) in subjects with HER2-positive, unresectable, or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology. 38(4_suppl). TPS460–TPS460. 7 indexed citations
5.
Hakenberg, Oliver W., José Luis Perez‐Gracia, Daniel Castellano, et al.. (2018). Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. European Journal of Cancer. 107. 186–195. 10 indexed citations
6.
Gerber, David E., Paul Swanson, Ariel López-Chávez, et al.. (2017). Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. Lung Cancer. 111. 108–115. 9 indexed citations
7.
Tap, William D., Robin L. Jones, Brian A. Van Tine, et al.. (2016). Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. The Lancet. 388(10043). 488–497. 436 indexed citations breakdown →
8.
Saif, Muhammad Wasif, James A. Knost, E. Gabriela Chiorean, et al.. (2016). Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer. Cancer Chemotherapy and Pharmacology. 78(4). 815–824. 56 indexed citations
9.
10.
Knost, James A., E. Gabriela Chiorean, Danni Yu, et al.. (2015). Phase I study of anti-VEGF receptor-3 (VEGFR-3) monoclonal antibody (mab) LY3022856/IMC-3C5 (3C5).. Journal of Clinical Oncology. 33(15_suppl). 3530–3530. 2 indexed citations
11.
Chiorean, E. Gabriela, Christopher Sweeney, Hagop Youssoufian, et al.. (2014). A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 73(3). 595–604. 50 indexed citations
12.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ashwin Shahir Breakdown of academic impact, for papers by Douglas Adkins Breakdown of academic impact, for papers by Hanna Koseła-Paterczyk Breakdown of academic impact, for papers by Nadia Hindi Breakdown of academic impact, for papers by Yvonne Schrage Breakdown of academic impact, for papers by Guowen Wang Breakdown of academic impact, for papers by Veridiana Pires de Camargo Breakdown of academic impact, for papers by Kelly Scheu Breakdown of academic impact, for papers by Thibaud Valentin Breakdown of academic impact, for papers by Zsuzsa Pápai
Rankless by CCL
2026